Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
m |
|||
Line 1: | Line 1: | ||
− | {| class="wikitable" style="text-align:center; width:50%;" | + | <!--{| class="wikitable" style="text-align:center; width:50%;" |
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' | ||
|- | |- | ||
Line 5: | Line 5: | ||
|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>The Ohio State University<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | |<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>The Ohio State University<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn] | ||
|- | |- | ||
− | |} | + | |}--> |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- |
Revision as of 12:25, 2 September 2019
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
ESMO
NCCN
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Giant-cell tumor of bone, all lines of therapy
Denosumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Thomas et. al 2010 | Phase II |
Chemotherapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive medications
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
28-day cycles
References
- Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed
Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy
- Malignant fibrous histiocytoma (MFH) of bone has been treated with osteosarcoma regimens